CBPO  China Biologic Products Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

2.82B

Vuru Grade

72.45/100

Current Price

$106.13
+0.38 (+0.36%)

Growth Price

$39.72
Overvalued by 62.57%

Stability Price

$22.13
Overvalued by 79.15%

Company Metrics

  • P/E 31.75
  • P/S 9.02
  • P/B 6.77
  • EPS 3.34
  • Cash ROIC 27.80%
  • Cash Ratio 2.02
  • Dividend 0 / N/A %
  • Avg. Vol. 251,672.00
  • Shares 26.57M
  • Market Cap. 2.82B

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Recently Issued Stock Ratings For China Biologic Products, Inc. (NASDAQ:CBPO)
Fiscal Standard - Jun 29, 2016
09/03/2014 - China Biologic Products, Inc. had its “buy” rating reiterated by analysts at Aegis Capital. They now have a USD 59 price target on the stock.
Oversold Conditions For China Biologic Products (CBPO)
Nasdaq - Jun 24, 2016
In trading on Friday, shares of China Biologic Products Inc (Symbol: CBPO) entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $101.01 per share.
Rudman Errol M Decreased Stake in China Biologic Prods INC (NASDAQ:CBPO) by $5 ...
Engelwood Daily - 3 hours ago
... $0.86 after the negative news, hitting $104.89 per share. About 38,106 shares traded hands. China Biologic Products Inc (NASDAQ:CBPO) has declined 10.77% since November 23, 2015 and is downtrending. It has underperformed by 10.02% the S&P500.
China Biologic Products, Inc. (NASDAQ:CBPO) Broker Price Targets For The ...
Fiscal Standard - Jun 26, 2016
01/07/2016 - China Biologic Products, Inc. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 162 price target on the stock.
China Biologic Products, Inc. versus ChemoCentryx, Inc. Head to Head Compare
CML News - Jun 23, 2016
This is a head to head comparison of China Biologic Products, Inc. (NASDAQ:CBPO) and ChemoCentryx, Inc. (NASDAQ:CCXI) .
China Biologic Products: An Alternative To The U.S Sector
Seeking Alpha - May 17, 2016
China Biologic Products Inc. is a mid cap biotech focused on plasma based technology. The firm manufactures twenty products for use in emergency rooms and in the treatment of immuno-deficiency related illnesses.
China Biologic Products, Inc. (NASDAQ:CBPO) Reports Basic Consolidated EPS At ... - Markets Daily
China Biologic Products, Inc. (NASDAQ:CBPO) Moderate Sell Ratings At 0
Markets Daily - Jun 23, 2016
China Biologic Products, Inc. (NASDAQ:CBPO) strong sell score is 0 while buy rating count is 0. Moderate sell ratings are 0 while moderate buy calls are 2. Hold ratings count is 1. As many as 1 brokerages initiated coverage on China Biologic Products, Inc.
China Biologic Products Inc (CBPO) Downgraded by Zacks Investment Research to Sell
South Florida Hedge Fund Managers - Apr 5, 2016
China Biologic Products logo China Biologic Products Inc (NASDAQ:CBPO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday, MarketBeat Ratings reports.
How Analysts Rated China Biologic Products Inc (NASDAQ:CBPO) Last Week?
Franklin Independent - Jun 21, 2016
Out of 7 analysts covering China Biologic Products (NASDAQ:CBPO), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive.
China Biologic Opens Plasma Collection Station in Hebei Province - PR Newswire (press release)
China Biologic Products, Inc. (NASDAQ:CBPO) Current Analyst Ratings - Fiscal Standard
China Biologic Products, Inc. (NASDAQ:CBPO) Has Been Assigned An Impact Score Of 0
Markets Daily - Jun 9, 2016
Alpha One has assigned an Impact score of 0.56 to China Biologic Products, Inc. (NASDAQ:CBPO) . This score will help the investors determine the stock sentiment on the company amongst investors.